Xenon Pharmaceuticals Inc. (XENE) News

Xenon Pharmaceuticals Inc. (XENE): $38.37

0.09 (-0.23%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add XENE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#236 of 360

in industry

Filter XENE News Items

XENE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XENE News Highlights

  • XENE's 30 day story count now stands at 5.
  • Over the past 5 days, the trend for XENE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about XENE are PRE, AES and DEC.

Latest XENE News From Around the Web

Below are the latest news stories about XENON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XENE as an investment opportunity.

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The common shares were offered at a public offering

Yahoo | December 4, 2023

After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain

Key Insights Significantly high institutional ownership implies Xenon Pharmaceuticals' stock price is sensitive to...

Yahoo | December 4, 2023

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Xenon will have another strong presence at AES this year, with many presentations and activities aimed at raising awareness about our XEN1101

Yahoo | December 2, 2023

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $32.50

Yahoo | November 30, 2023

Xenon Pharmaceuticals Announces Proposed Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement. All of the common shares and pre-funded warrants in this off

Yahoo | November 29, 2023

Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.

Yahoo | November 28, 2023

The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring

Biotech stock Xenon rocketed Monday, after its experimental epilepsy drug unexpectedly showed promise in depression treatment.

Yahoo | November 27, 2023

UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study

Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study. Still, the company said it was actively exploring future development of the drug candidate, XEN1101, as a treatment for MDD. Xenon said the study data was compelling, building upon the ongoing late-stage study for the use of XEN1101 in treating epilepsy.

Yahoo | November 27, 2023

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

Conference call today at 8:30 am ETVANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD. Summary of

Yahoo | November 27, 2023

Xenon drug misses main goal of depression study

Yet, the company believes there were enough positive findings in the mid-stage trial to warrant further study of its drug, called XEN1101, in depression.

Yahoo | November 27, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!